Start Date
December 31, 2017
Primary Completion Date
December 1, 2018
Study Completion Date
December 31, 2019
Iodine (124I) Girentuximab
i.v.
Memorial Sloan-Kettering Cancer Center, New York
Duke University Medical Center, Durham
H. Lee Moffitt Cancer Center & Research Center, Tampa
Ohio State University, Columbus
David Geffen School of Medicine, UCLA, Los Angeles
Lahey Clinic, Burlington
Fox Chase Cancer Center, Philadelphia
MD Anderson, Houston
Lead Sponsor
Heidelberg Pharma AG
INDUSTRY